Phase 3 Clinical Trials
Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment
Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment
AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial
AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data
Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor
Ultragenyx Advances Gene Therapy for Glycogen Storage Disease Type Ia Following Phase 3 Success
Ultragenyx, gene therapy, glycogen storage disease type Ia, DTX401, Phase 3 study, GlucoGene, rare genetic diseases
FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval
FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials
Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment
Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value
Novartis Achieves Success in Two Phase III Trials for Rare Kidney Diseases, Eyes Regulatory Submissions
Novartis, Phase III trials, Rare kidney diseases, IgA nephropathy, C3 glomerulopathy, Regulatory submissions
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment
Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment
J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.